Published in Ann Transl Med on May 01, 2016
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer | NCT01621243
BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer | NCT01571024
Afatinib as Cancer Therapy for Exocrine Pancreatic Tumours (ACCEPT) | NCT01728818
Investigator's Initiated Phase II Study for Pancreatic Cancer Patients | NCT01659502
CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | NCT00075647
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Cancer statistics, 2015. CA Cancer J Clin (2015) 57.51
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med (2011) 24.32
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med (2013) 16.24
Regulation of cancer cell metabolism. Nat Rev Cancer (2011) 15.44
Pancreatic cancer. N Engl J Med (2010) 13.88
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med (2004) 13.34
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2006) 8.26
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 7.57
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36
International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology (2012) 7.22
Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res (2014) 7.15
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg (1985) 7.14
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature (2013) 6.53
RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer (2011) 6.45
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 6.44
Pancreatic adenocarcinoma. N Engl J Med (2014) 6.21
Pancreatic cancers require autophagy for tumor growth. Genes Dev (2011) 6.17
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature (2013) 4.71
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol (2010) 4.69
p53 status determines the role of autophagy in pancreatic tumour development. Nature (2013) 4.31
Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med (2010) 4.13
Whole genomes redefine the mutational landscape of pancreatic cancer. Nature (2015) 4.01
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol (2009) 3.61
Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res (2008) 3.59
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol (2004) 3.56
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA (2013) 3.46
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol (2011) 3.44
Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 3.36
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature (2014) 3.34
The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med (2013) 3.20
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer (2008) 3.19
Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science (1991) 3.14
Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med (2014) 3.09
Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology (2012) 2.74
Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc Natl Acad Sci U S A (2013) 2.57
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer (2002) 2.53
History of oncolytic viruses: genesis to genetic engineering. Mol Ther (2007) 2.51
Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther (2007) 2.50
Precursors to invasive pancreatic cancer. Adv Anat Pathol (2005) 2.45
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol (2008) 2.40
Targeted therapies: a new generation of cancer treatments. Am Fam Physician (2008) 2.36
Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest (2007) 2.36
Going viral with cancer immunotherapy. Nat Rev Cancer (2014) 2.27
Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology (2009) 2.17
European cancer mortality predictions for the year 2014. Ann Oncol (2014) 2.11
Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res (2015) 2.11
Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep (2011) 2.09
Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell (2004) 2.05
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol (2008) 2.04
Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. Nature (2015) 2.00
Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut (2011) 1.94
Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther (2011) 1.87
The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. Nat Cell Biol (2014) 1.87
KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci (2014) 1.85
Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980. Ann Oncol (2013) 1.79
Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol (2012) 1.73
Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Proc Natl Acad Sci U S A (2015) 1.69
Pancreatic adenocarcinoma. N Engl J Med (2014) 1.67
Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol (2011) 1.65
Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res (2003) 1.63
Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets (2007) 1.62
Roles for KRAS in pancreatic tumor development and progression. Gastroenterology (2013) 1.61
Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int J Mol Med (2003) 1.61
De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res (2010) 1.59
Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg (2010) 1.56
Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech (2013) 1.55
Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther (2009) 1.54
Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res (2009) 1.50
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs (2011) 1.49
European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol (2015) 1.47
BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Lett (2006) 1.46
Mood and anxiety disorders as early manifestations of medical illness: a systematic review. Psychother Psychosom (2014) 1.46
The impact of curative intent surgery on the survival of pancreatic cancer patients: a U.S. Population-based study. Am J Gastroenterol (2007) 1.43
Famine versus feast: understanding the metabolism of tumors in vivo. Trends Biochem Sci (2015) 1.42
Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One (2011) 1.39
Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol (2014) 1.33
The Notch pathway in cancer: differentiation gone awry. Eur J Cancer (2005) 1.33
Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles. Viruses (2010) 1.30
Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest (2004) 1.26
Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res (2014) 1.23
Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas. Ann Surg (2012) 1.22
In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer (2006) 1.20
Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin Cancer Res (2001) 1.20
Improving outcome for patients with pancreatic cancer through centralization. Br J Surg (2011) 1.19
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer (2014) 1.17
Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Cancer Treat Rev (2013) 1.16
Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist (2014) 1.15
Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Mol Ther (2010) 1.12
Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res (2006) 1.12